Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001636282-24-000066
Filing Date
2024-10-01
Accepted
2024-10-01 18:26:50
Documents
3
Period of Report
2024-10-01

Document Format Files

Seq Description Document Type Size
1 FORM 3 wk-form3_1727821603.html 3  
1 FORM 3 wk-form3_1727821603.xml 3 1687
2 EX-24 poa-sheldonsloanconforme.htm EX-24 3854
3 GRAPHIC poa-sheldonsloanconforme001.jpg GRAPHIC 226639
  Complete submission text file 0001636282-24-000066.txt   319370
Mailing Address 221 CRESCENT STREET BUILDING 23, SUITE 105 WALTHAM MA 02453
Business Address 221 CRESCENT STREET BUILDING 23, SUITE 105 WALTHAM MA 02453 6176515940
Spyre Therapeutics, Inc. (Issuer) CIK: 0001636282 (see all company filings)

EIN.: 464312787 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 221 CRESCENT STREET SUITE 105 WALTHAM MA 02453
Business Address
Sloan Sheldon (Reporting) CIK: 0002038798 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-37722 | Film No.: 241344724